Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays.
暂无分享,去创建一个
Manuel Salto-Tellez | M. Salto‐Tellez | Daohai Zhang | T. Putti | E. Do | E. Koay | Daohai Zhang | Evelyn S C Koay | Elaine Do | Thomas Choudary Putti
[1] K. Kono,et al. Status of c‐erbB‐2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme‐linked immuno‐sorbent assay , 2002, International journal of cancer.
[2] E. Frenkel,et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays , 2000, Journal of clinical pathology.
[3] D. Slamon,et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Y. Saito,et al. Detection of numerical aberration in chromosome 17 and c-erbB2 gene amplification in epithelial ovarian cancer using recently established dual color FISH. , 2001, European journal of gynaecological oncology.
[5] R. Ridolfi,et al. HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach , 2000, Modern Pathology.
[6] J. Fletcher,et al. HER-2/neu (c-erb-B2) gene and protein in breast cancer. , 1999, American journal of clinical pathology.
[7] C. Sheehan,et al. Comparison of HER-2/ neu Oncogene Amplification Detected by Fluorescence In Situ Hybridization in Lobular and Ductal Breast Cancer , 2002, Applied immunohistochemistry & molecular morphology : AIMM.
[8] D. Pinkel,et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[9] H. Tsuda,et al. Detection of HER‐2/neu (c‐erb B‐2) DNA amplification in primary breast carcinoma , 2001, Cancer.
[10] C. Sheehan,et al. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. , 1997, Human pathology.
[11] T. Grogan,et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Mottolese,et al. Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer. , 2002, Cancer genetics and cytogenetics.
[13] Y. Oda,et al. Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. , 2002, Human pathology.
[14] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[15] N. Sneige,et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. , 2000, American journal of clinical pathology.
[16] A. Vincent-Salomon,et al. Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma , 2000, Modern Pathology.
[17] D. Slamon,et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] W. Wells,et al. The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[19] Benjamin D. Smith,et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] E. Frenkel,et al. Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu Status , 2002, Modern Pathology.
[21] D. Visscher,et al. Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization , 2000, Modern Pathology.
[22] H A Lehr,et al. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. , 2001, American journal of clinical pathology.
[23] F. Hirsch,et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas , 2002, British Journal of Cancer.
[24] D. Slamon,et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.
[25] S J Schnitt,et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Potti,et al. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. , 2002, Lung cancer.
[27] R. Xu,et al. Amplification of Her-2/neu Gene in Her-2/neu-Overexpressing and -Nonexpressing Breast Carcinomas and Their Synchronous Benign, Premalignant, and Metastatic Lesions Detected by FISH in Archival Material , 2002, Modern Pathology.
[28] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[29] M. Kraus,et al. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. , 1989, Genomics.
[30] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Ross,et al. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer. , 1999, American journal of clinical pathology.
[32] W. McGuire,et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.
[33] H. Earp,et al. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research , 1995, Breast Cancer Research and Treatment.
[34] M. Salto‐Tellez,et al. Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast Cancer , 2003, Modern Pathology.
[35] T. Visakorpi,et al. Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.